A Phase I/II Study of Brentuximab (SGN-35) in Pediatric Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma or Hodgkin Lymphoma
[Protocol 11-210] |
Trippett, Tanya |
- Lymphoma
- Hodgkin's Disease
- Non-Hodgkin's Lymphoma
|
A Phase I/II Study of Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Patients with Relapsed/Refractory Indolent B-cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
[Protocol 05-103] |
Gerecitano, John |
- Leukemia
- Chronic Lymphocytic Leukemia
- Lymphoma
|
A Phase I/II Study of AT7519M with and without Bortezomib in Patients with Previously Treated Multiple Myeloma
[Protocol 10-151] |
Landau, Heather |
|
A Phase I/II Clinical Trial of Temsirolimus plus Neratinib for Patients with Metastatic HER2-Amplified or Triple-Negative Breast Cancer
[Protocol 10-005] |
Chandarlapaty, Sarat |
|
A Phase I/II Clinical Study of Vorinostat Plus Etoposide in Pediatric Patients with Refractory Solid Tumors
[Protocol 10-096] |
Trippett, Tanya |
|
A Phase I-II Study of Dasatinib plus Paclitaxel in Patients with Metastatic Breast Cancer
[Protocol 08-122] |
Fornier, Monica |
|
A Phase I Trial of NECTAR: Nelarabine, Etoposide, and Cyclophosphamide in Children with T-Cell Acute Lymphoblastic Leukemia
[Protocol 11-119] |
Trippett, Tanya |
- Leukemia
- Acute Lymphoblastic Leukemia
|
A Phase I Trial of Gemcitabine and Split-Dose Cisplatin plus Everolimus in Patients with Advanced Urothelial Cancer
[Protocol 10-106] |
Bajorin, Dean |
|
A Phase I Trial of B-Cell Acute Lymphoblastic Leukemia Treated with Autologous T Cells Gene-Targeted to the B-Cell Antigen CD19
[Protocol 09-114] |
Davila, Marco |
- Leukemia
- Acute Lymphoblastic Leukemia
|
A Phase I Trial of a Trivalent Vaccine with Escalating Doses of the Immunological Adjuvant OPT-821 Plus Oral ß-Glucan for High-Risk Neuroblastoma
[Protocol 05-075] |
Kushner, Brian |
|
A Phase I Trial of a New Vaccine (Globo-H-GM2-sTn-TF-Tn) for Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission
[Protocol 09-184] |
Sabbatini, Paul |
|
A Phase I Study of Yttrium-90 Attached to Chimeric Monoclonal Antibody CG250 in Patients with Advanced Renal Cancer
[Protocol 05-031] |
Larson, Steven |
|
A Phase I Study of Xenogeneic CD20 DNA Vaccination in Patients with B-cell Lymphoma
[Protocol 07-100] |
Palomba, M. Lia |
|
A Phase I Study of WT1-Specific T Cells for the Treatment of Patients with Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Cancers
[Protocol 06-155] |
O'Cearbhaill, Roisin |
|
A Phase I Study of WT1-Specific Donor-Derived T Cells in Patients with Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia after T-Cell-Depleted Allogeneic Stem Cell Transplantation
[Protocol 12-175] |
Koehne, Guenther |
|
A Phase I Study of WT1-Sensitized T cells for Residual or Relapsed Leukemia after Allogeneic Hematopoietic Progenitor Cell Transplantation
[Protocol 07-055] |
O'Reilly, Richard |
|
A Phase I Study of Whole Brain Radiation Therapy plus Sorafenib for Patients with Breast Cancer Brain Metastases
[Protocol 12-046] |
Seidman, Andrew |
- Brain Tumors, Metastatic
- Breast Cancer
|
A Phase I Study of VTX-2337 Plus Doxil in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
[Protocol 11-110] |
Bell-McGuinn, Katherine |
|
A Phase I Study of Vemurafenib in Adolescents with Inoperable Stage IIIC/IV Melanoma with V600 BRAF Mutations
[Protocol 11-198] |
Pratilas, Christine |
|
A Phase I Study of Veliparib Given with Radiation Therapy to the Chest Wall and Lymph Nodes in Patients with Inflammatory or Recurrent Breast Cancer
[Protocol 12-215] |
Ho, Alice |
|
